Form 8-K

8-K — DYADIC INTERNATIONAL INC

Accession: 0001493152-26-028700

Filed: 2026-06-15

Period: 2026-06-15

CIK: 0001213809

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

GRAPHIC (form8-k_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001213809

2026-06-15

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (date of earliest event reported): June 15, 2026

Dyadic

International, Inc.

(Exact

name of registrant as specified in its charter)

Delaware

001-32513

45-0486747

(State

or other jurisdiction

incorporation or organization)

(Commission

File

Number)

(I.R.S.

Employer

Identification

Number)

1044

North U.S. Highway One, Suite 201

Jupiter,

FL 33477

(Address

of principal executive offices and zip code)

(561)

743-8333

(Registrant’s

telephone number, including area code)

N/A

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

Stock, par value $0.001 per share

DYAI

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)

or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01. Regulation

FD Disclosure.

June 15, 2026, Dyadic International, Inc. (the “Company” or “Dyadic”) issued a press release titled “Dyadic

Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption”.

The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The

information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall

not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange

Act”), or otherwise subject to the liabilities of such section. Such information shall not be incorporated by reference in any

filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference

in such a filing.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits:

Exhibit

Number

Description

99.1

Dyadic International, Inc. Press Release Dated June 15, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date:

June 15, 2026

Dyadic

International, Inc.

By:

/s/

Ping Rawson

Name:

Ping

Rawson

Title:

Chief

Financial Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit

99.1

Dyadic

Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

Company’s

C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization

across life sciences, food, nutrition and industrial markets

JUPITER,

Fla., June 15, 2026 — Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolutions (“Dyadic”

or the “Company”), a biotechnology company focused on the development and commercialization of scalable microbial protein

production platforms, today highlighted increasing interest in its proprietary C1 protein production platform as global infectious disease

preparedness efforts intensify in response to the ongoing Bundibugyo Ebola virus (BDBV) outbreak and as the Company continues to advance

commercial adoption across multiple high-growth markets.

The

recent Ebola-related preparedness activity has brought renewed attention to one of the most important challenges in global health: the

ability to rapidly manufacture vaccines, monoclonal antibodies and other biologics at sufficient scale and affordable cost. Dyadic believes

its C1 platform is well positioned to help address this challenge through rapid strain development, high expression levels, flexible

microbial manufacturing and reduced production timelines.

Dyadic’s

C1 platform has demonstrated the ability to progress from receipt of a codon-optimized viral gene sequence to purified recombinant antigen

or monoclonal antibody in approximately 15 days. The Company believes this speed may be particularly important during infectious disease

outbreaks, where response time, manufacturing capacity and equitable access can directly affect preparedness outcomes.

“Recent

outbreaks continue to demonstrate that speed matters,” said Mark A. Emalfarb, Chief Executive Officer of Dyadic Applied BioSolutions.

“Scientific discovery alone is not enough. Vaccines and antibody therapies that cannot be manufactured quickly, affordably and

at sufficient scale are unable to reach the people who need them most. A vaccine or antibody that is unavailable or unaffordable is 100%

ineffective. Manufacturing matters.”

Ebola

Preparedness Creates Timely Interest in Rapid Biomanufacturing

The

Bundibugyo Ebola virus outbreak has led to enhanced surveillance, traveler screening, border monitoring and other public health measures

associated with international travel and large public gatherings, such as the FIFA World Cup. These activities underscore the need for

technologies that can support the rapid development, production and release of vaccines and antibody therapies during infectious disease

threats.

Dyadic

is experiencing growing interest in the potential application of its C1 microbial protein production platform for Ebola-related vaccine

antigen and monoclonal antibody development programs. This interest reflects the growing need for technologies that can support rapid,

scalable and cost-effective biologics manufacturing during infectious disease outbreaks.

Dyadic’s

recently announced collaboration with Scripps Research represents one important track. The collaboration combines Scripps’ expertise

in computational antigen design and viral immunology with Dyadic’s C1 protein production platform. Together, the organizations

are evaluating approaches that may accelerate the development and production of vaccine antigens and monoclonal antibody candidates for

infectious diseases, including Ebola, hantaviruses and other emerging viral threats.

second track involves research proposals submitted in response to CEPI’s Ebola funding call that incorporate Dyadic’s C1

platform to support vaccine development and manufacturing. These submissions are focused on evaluating the potential use of C1 to support

rapid vaccine antigen development and scalable manufacturing for Ebola preparedness.

third track involves an additional monoclonal antibody initiative with Fondazione Biotecnopolo di Siena and the European Vaccines Hub.

This initiative is focused on antibody programs targeting Ebola and hantavirus infections and further highlights the potential application

of Dyadic’s C1 platform beyond vaccine antigen production and into scalable monoclonal antibody manufacturing.

Together,

these three tracks underscore the growing relevance of Dyadic’s C1 platform in infectious disease preparedness, spanning vaccine

antigen development, monoclonal antibody production and scalable biologics manufacturing.

Platform Addresses a Critical Bottleneck: Manufacturing

Dyadic

believes that as artificial intelligence has the potential to accelerate the discovery of new antibodies, antigens, enzymes and other

proteins, scalable manufacturing platforms can play an increasingly important role in converting scientific innovation into real-world

products.

The

Company believes the C1 platform’s rapid strain development, high expression levels, use of standard microbial bioreactors, flexible

manufacturing profile and potential cost advantages can help support regional manufacturing initiatives focused on vaccines, monoclonal

antibodies and other biologics.

Through

collaborations and grants involving organizations such as CEPI, the Gates Foundation, the European Vaccines Hub and Fondazione Biotecnopolo

di Siena, Dyadic continues to advance and further validate its C1 platform. In addition, Dyadic’s DYAI-100 clinical study demonstrated

that C1-produced antigens were generally safe and well tolerated, supporting the potential use of the platform for recombinant protein-based

vaccine applications.

“Ebola

preparedness is a timely example of why Dyadic’s platform matters,” Emalfarb said. “But the opportunity is much broader.

The same capabilities being evaluated for outbreak preparedness are also being used to support commercial products across life sciences,

food, nutrition and industrial markets.”

Commercial

Adoption Expands Beyond Pandemic Preparedness

While

infectious disease preparedness provides a high-profile and urgent use case for Dyadic’s technology, the Company is also leveraging

its protein production capabilities to commercialize recombinant proteins and enzymes across multiple markets.

Recent

commercial and development milestones include:

● Launch

of recombinant human albumin through Proliant Health & Biologicals

● Commercialization

of recombinant DNase I through Fermbox Bio

● Global

distribution activities through IBT Bioservices

● Commercialization

of recombinant bovine chymosin through Inzymes

● Advancement

of recombinant transferrin and growth factor products targeting cell culture media, cultivated

meat, biomanufacturing and other high-growth life sciences applications

Dyadic

believes these programs demonstrate that its C1 and Dapibus™ platforms are not limited to one disease, one product or one market.

Instead, the Company is pursuing a diversified commercialization strategy that may include product sales, licensing, royalties, funded

collaborations, supply relationships and strategic partnerships.

Multiple

Markets, Multiple Shots on Goal

Dyadic’s

C1 and Dapibus™ platforms are being developed to support recombinant protein production across several major categories:

Biopharmaceutical

and Pandemic Preparedness: vaccine antigens, monoclonal antibodies, infectious disease response and regional biologics manufacturing.

Life

Sciences and Biomanufacturing: recombinant albumin, DNase I, transferrin, growth factors, diagnostics, cell culture media and bioprocessing

inputs.

Food,

Nutrition and Wellness: animal-free proteins, dairy and other enzymes, precision fermentation ingredients and sustainable nutrition

applications.

Industrial

Biotechnology: enzymes and specialty proteins for industrial processes, sustainability-focused manufacturing and bioindustrial applications.

The

Company believes this multi-market approach provides several potential pathways for long-term value creation while reducing dependence

on any single clinical program, outbreak event or commercial product.

Dyadic

Positioned at the Intersection of Global Health, AI and Scalable Protein Manufacturing

Dyadic

believes the convergence of emerging infectious disease preparedness, AI-enabled protein discovery, and growing demand for animal-free

and recombinant proteins is creating an opportunity for its scalable dual protein production platforms across global health and commercial

markets.

governments, global health organizations, biotechnology companies and academic institutions evaluate approaches to outbreak preparedness

and equitable access to biologics, Dyadic believes manufacturing capacity, scalability, speed and cost efficiency are becoming increasingly

important considerations.

“What

makes this particularly exciting for Dyadic is that we have two complementary protein production platforms designed to serve distinct

but significant markets,” Emalfarb said. “Our C1 platform is focused on life sciences and biopharmaceutical applications,

including pandemic preparedness, vaccine antigens, monoclonal antibodies, other biologics, diagnostics and cell culture inputs. Our Dapibus™

platform is designed to support the commercialization of recombinant proteins and enzymes across food, nutrition, wellness and bioindustrial

markets, including animal-free ingredients, precision fermentation, specialty enzymes and industrial biotechnology applications. Together,

these platforms are targeting current addressable market opportunities that Dyadic estimates exceed $25 billion across life sciences,

food/nutrition, wellness and bioindustrial applications. As demand continues to grow for biologics, animal-free proteins, cell culture

inputs and industrial enzymes, we believe Dyadic’s platforms are increasingly well positioned to support both global health initiatives

and commercial market opportunities.”

About

Dyadic Applied BioSolutions

Dyadic

Applied BioSolutions is a global biotechnology company that aims to develop and commercialize scalable, non-animal protein production

platforms to meet growing global demand across the life sciences, food and nutrition, and bio-industrial markets. These high-value proteins

are designed to enable customers to develop more efficient, scalable, and sustainable products. Dyadic’s proprietary Dapibus™

and C1 expression systems support rapid, cost-effective, and flexible manufacturing.

For

more information, please visit http://www.dyadic.com.

Safe

Harbor Regarding Forward-Looking Statements

This

press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange

Act, including those regarding Dyadic International’s expectations, intentions, strategies, and beliefs pertaining to future events

or future financial performance, such as the success of our clinical trial and interest in our protein production platforms, our research

projects and third-party collaborations, as well as the availability of necessary funding. Forward-looking statements generally can be

identified by use of the words “expect,” “should,” “intend,” “anticipate,” “will,”

“project,” “may,” “might,” “potential,” or “continue” and other similar terms

or variations of them or similar terminology. Dyadic International, Inc., and its subsidiaries caution readers that any forward-looking

information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking

information. Such statements reflect the current views of our management with respect to our operations, results of operations and future

financial performance. Forward-looking statements involve many risks, uncertainties, or other factors beyond Dyadic’s control.

These factors include, but are not limited to (i) our history of net losses; (ii) market and regulatory acceptance of our microbial protein

production platforms and other technologies; (iii) failure to commercialize our microbial protein production platforms or our other technologies;

(iv) competition, including from alternative technologies; (v) the results of nonclinical studies and clinical trials; (vi) our capital

needs; (vii) changes in global economic and financial conditions; (viii) our reliance on information technology; (ix) our dependence

on third parties; (x) government regulations and environmental, social and governance issues; (xi) intellectual property risks; (xii)

our ability to comply with the listing standards of the Nasdaq Stock Market LLC; and (xii) other factors discussed in Dyadic’s

publicly available filings, including information set forth under the caption “Risk Factors” in Dyadic’s annual report

on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 25, 2026, as amended on April 30, 2026, and

quarterly report on Form 10-Q filed with the SEC on May 13, 2026, as such factors may be updated from time to time in Dyadic’s

periodic filings with the SEC, which are accessible on the SEC’s website and at www.dyadic.com. The forward-looking statements

contained in this press release are made only as of the date hereof, and except as required by law, we undertake no obligation to publicly

update any forward-looking statements for any reason after the date of this press release to conform these statements to actual results

or to changes in our expectations.

Media

contacts:

Dyadic

Applied BioSolutions:

Ping

Rawson

Chief

Financial Officer

Phone:

(561) 743-8333

Email:

ir@dyadic.com

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (11619 bytes)

Download ex99-1_001.jpg

GRAPHIC

Filename: form8-k_001.jpg · Sequence: 4

Binary file (7531 bytes)

Download form8-k_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Jun. 15, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 15, 2026

Entity File Number

001-32513

Entity Registrant Name

Dyadic

International, Inc.

Entity Central Index Key

0001213809

Entity Tax Identification Number

45-0486747

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1044

North U.S. Highway One

Entity Address, Address Line Two

Suite 201

Entity Address, City or Town

Jupiter

Entity Address, State or Province

Entity Address, Postal Zip Code

33477

City Area Code

(561)

Local Phone Number

743-8333

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001 per share

Trading Symbol

DYAI

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration